Jaishree Jeyaraman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jaishree Jeyaraman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Akansha Shukla
Department of Chemical Engineering
3 shared publications- Sri Sivakumar
Department of Chemical Engineering, Indian Institute of Technology, Kanpur, India
2 shared publications - Andrew Michael Jackson
School of Medicine, Center for Cancer Sciences, University of Nottingham, Nottingham, UK
1 shared publication Anna Malecka
Host-Tumour Interactions Group
1 shared publication- Annie Abraham
Department of Biochemistry, University of Kerala, Kariavattom, Thiruvananthapuram, India
1 shared publication Barsha Marandi
Department of Chemical Engineering
1 shared publication
Latest Publications
- 26 May 2017
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 5 (26) , 5251-5258
Immuno-silent polymer capsules encapsulating nanoparticles for bioimaging applications
PEGylated polymer capsules encapsulating LaVO 4 :Tb 3+ , GdVO 4 :Tb 3+ , Gd 2 O 3 :Tb 3+ , GdF 3 :Tb 3+ , YVO 4 :Tb 3+ and iron oxide nanoparticles are promising new fluorescence, magnetic and magnetofluorescence imaging agents.
- 26 May 2017
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 5 (26) , 5251-5258
Immuno-silent polymer capsules encapsulating nanoparticles for bioimaging applications
PEGylated polymer capsules encapsulating LaVO 4 :Tb 3+ , GdVO 4 :Tb 3+ , Gd 2 O 3 :Tb 3+ , GdF 3 :Tb 3+ , YVO 4 :Tb 3+ and iron oxide nanoparticles are promising new fluorescence, magnetic and magnetofluorescence imaging agents.
- 18 July 2016
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 2 (8) , 1330-1340
Targeted Stealth Polymer Capsules Encapsulating Ln3+-Doped LaVO4 Nanoparticles for Bioimaging Applications
We report synthesis of targeted PEGylated polymer capsules encapsulating Stoke’s shift and upconverting LaVO4 nanoparticles by following a unique approach for bioimaging applications. First, LaVO4:Ln3+@silica (Ln3+= Tb3+, Eu3+, and Yb3+/Er3+) core-shell nanoparticles are prepared by sol-gel method followed by layer-by-layer assembly of polymers and PEGylation over core-shell particles. Second, removal of silica core facilitates the trapping of LaVO4:Ln3+ nanoparticles inside the PEGylated polymer capsules. Finally, capsules are surface modified with antibodies to target cancer cells. The nanoparticles-loaded polymer capsules are found to be internalized and biocompatible with various cells (e.g. HeLa, A498, H460, MCF-7, Schwann, L929, and IC-21) suggesting their applicability in different types of cells. In addition, the capsules modified with antibodies show more specific uptake suggesting their targeting ability by 3-fold for MCF-7 and 10-fold for H460 cancer cells. Moreover, the nanoparticles-loaded polymer capsules were internalized by HeLa cells via macropinocytosis mechanism. We observed localized bright Stoke’s shift (Tb3+ ions, λex = 488 nm) and upconversion (Er3+ ions, λex = 980 nm) green fluorescence from cells suggesting their potential use as targeted bioimaging agents. KEYWORDS: LaVO4, PEGylated polymer capsules, cell uptake mechanism, upconversion lanthanide ions, Ln3+ doped nanoparticles, bioimaging.
- 18 July 2016
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 2 (8) , 1330-1340
Targeted Stealth Polymer Capsules Encapsulating Ln3+-Doped LaVO4 Nanoparticles for Bioimaging Applications
We report synthesis of targeted PEGylated polymer capsules encapsulating Stoke’s shift and upconverting LaVO4 nanoparticles by following a unique approach for bioimaging applications. First, LaVO4:Ln3+@silica (Ln3+= Tb3+, Eu3+, and Yb3+/Er3+) core-shell nanoparticles are prepared by sol-gel method followed by layer-by-layer assembly of polymers and PEGylation over core-shell particles. Second, removal of silica core facilitates the trapping of LaVO4:Ln3+ nanoparticles inside the PEGylated polymer capsules. Finally, capsules are surface modified with antibodies to target cancer cells. The nanoparticles-loaded polymer capsules are found to be internalized and biocompatible with various cells (e.g. HeLa, A498, H460, MCF-7, Schwann, L929, and IC-21) suggesting their applicability in different types of cells. In addition, the capsules modified with antibodies show more specific uptake suggesting their targeting ability by 3-fold for MCF-7 and 10-fold for H460 cancer cells. Moreover, the nanoparticles-loaded polymer capsules were internalized by HeLa cells via macropinocytosis mechanism. We observed localized bright Stoke’s shift (Tb3+ ions, λex = 488 nm) and upconversion (Er3+ ions, λex = 980 nm) green fluorescence from cells suggesting their potential use as targeted bioimaging agents. KEYWORDS: LaVO4, PEGylated polymer capsules, cell uptake mechanism, upconversion lanthanide ions, Ln3+ doped nanoparticles, bioimaging.
- 31 May 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (60) , 55125-55134
Bio-distribution and in vivo/in vitro toxicity profile of PEGylated polymer capsules encapsulating LaVO4:Tb3+nanoparticles for bioimaging applications
Lanthanide-doped nanoparticles are being explored for bioimaging applications owing to their unique optical properties. However, their toxicity profiles have not been explored in detail at the in vivo level which is a pre-requisite for clinical use. To this end, we have investigated a detailed in vivo/in vitro toxicity profiling of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles. First, in vitro toxicity studies were carried out in L929 mouse fibroblast cells in which MTT assay, neutral red uptake (NRU) assay, LDH release, cell morphology; quantification of reactive nitrogen species (RNS), reactive oxygen species (ROS), lipid peroxidation level, caspase-3 activity, and apoptosis assay were also performed. Second, in vivo studies were carried out in Swiss Albino mice, which included biodistribution studies (6 h and 24 h), evaluation of hematological parameters, and toxicity marker enzyme levels (inflammation, oxidative stress, tissue infiltration, liver dysfunction, etc.), organ histology, and genotoxocity. The detailed investigation of toxicity at in vitro and in vivo levels indicates the biocompatibility of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles proving their suitability for bio-imaging applications.
- 31 May 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (60) , 55125-55134
Bio-distribution and in vivo/in vitro toxicity profile of PEGylated polymer capsules encapsulating LaVO4:Tb3+nanoparticles for bioimaging applications
Lanthanide-doped nanoparticles are being explored for bioimaging applications owing to their unique optical properties. However, their toxicity profiles have not been explored in detail at the in vivo level which is a pre-requisite for clinical use. To this end, we have investigated a detailed in vivo/in vitro toxicity profiling of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles. First, in vitro toxicity studies were carried out in L929 mouse fibroblast cells in which MTT assay, neutral red uptake (NRU) assay, LDH release, cell morphology; quantification of reactive nitrogen species (RNS), reactive oxygen species (ROS), lipid peroxidation level, caspase-3 activity, and apoptosis assay were also performed. Second, in vivo studies were carried out in Swiss Albino mice, which included biodistribution studies (6 h and 24 h), evaluation of hematological parameters, and toxicity marker enzyme levels (inflammation, oxidative stress, tissue infiltration, liver dysfunction, etc.), organ histology, and genotoxocity. The detailed investigation of toxicity at in vitro and in vivo levels indicates the biocompatibility of PEGylated polymer capsules encapsulating LaVO4:Tb3+ nanoparticles proving their suitability for bio-imaging applications.